DEA Labels Lab Buzz as Cannabimimetic Schedule I Threats
Published Date: 1/20/2026
Rule
Summary
Starting February 19, 2026, the DEA is officially defining “cannabimimetic agents” and adding 18 new substances to this group, all still Schedule I drugs. They’re also simplifying things by giving most of these substances one single drug code, making tracking easier. This update affects manufacturers, law enforcement, and anyone handling these substances, but it won’t change their legal status or cause new fees.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Eighteen substances formally listed
Starting February 19, 2026, DEA adds 18 additional named substances to the definition of “cannabimimetic agents.” All 18 substances remain Schedule I controlled substances, so their legal schedule status does not change.
Single DEA drug code for most agents
DEA consolidates most existing administration controlled substances codes for cannabimimetic agents into a single drug code number 7000 when the rule takes effect on February 19, 2026, to simplify tracking and reporting.
Two substances moved but keep existing codes
JWH-018 and AM2201 are moved to 21 CFR 1308.11(d) but retain their existing drug codes (7118 and 7201) to facilitate quota and international reporting; upon that move, positional isomers of these two substances will be defined as Schedule I controlled substances.
No new fees or reporting obligations
DEA states this final rule does not change the Schedule I status of listed substances, does not impose new regulatory controls, recordkeeping, reporting requirements, or information-collection burdens, and will not create new fees for handlers.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06051 — Importer of Controlled Substances Application: Usona Institute
Usona Institute wants to become an official importer of some powerful controlled substances like mescaline and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by April 29, 2026. This move could impact research and medical use, with no direct cost changes announced yet.
2026-05912 — Bulk Manufacturer of Controlled Substances Application: SpecGx LLC
SpecGx LLC wants to become a big-time maker of some powerful and tightly controlled drugs, including things like psilocybin and fentanyl. People and companies already registered can share their thoughts or ask for a hearing by May 26, 2026. This move could shake up how these substances are made and handled, so keep an eye on the deadlines if you’re involved!
2026-05618 — Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I
Starting April 22, 2026, the DEA is putting 3-methoxyphencyclidine (3-MeO-PCP) into Schedule I, meaning it’s now officially a highly controlled substance with strict rules. This affects anyone who makes, sells, studies, or even possesses 3-MeO-PCP, who will face serious legal consequences. This move helps the U.S. follow international drug laws and keeps communities safer.
2026-05482 — Ordering Schedule I and II Controlled Substances Using DEA Form 222; Technical Amendments
If you order Schedule I or II drugs using DEA Form 222, this update clears up who can sign and manage the form—only registrants, their partners, or officers can do it. It also removes old rules about the old triplicate form, making things simpler and clearer. These fixes don’t change any big rules and take effect on March 20, 2026, so no extra costs or hassles ahead!
2026-05486 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) just updated which chemical mixes are officially exempt from strict drug rules between September 2024 and December 2025. Companies and labs using these chemicals should check the new list to see if their products are approved or denied. You’ve got until May 19, 2026, to share your thoughts, and no extra fees are involved—just a quick review and comment if you want!
2026-05359 — Importer of Controlled Substances Application: United States Pharmacopeial Convention
The United States Pharmacopeial Convention wants to become an official importer of certain controlled substances like Cathinone and Methcathinone. If you’re a registered manufacturer or interested party, you have until April 20, 2026, to share your thoughts or ask for a hearing. This move could impact how these substances are imported and tracked, but no direct costs are mentioned.
Previous / Next Documents
Previous: 2026-00904 — Commercial Non-Power Production or Utilization Facilities
The Nuclear Regulatory Commission just clarified that commercial non-power nuclear facilities must follow certain safety update rules, while non-commercial ones don’t. This change kicks in right away and affects businesses running these facilities, who now have 30 days to share their thoughts. No new fees are mentioned, but staying in the loop is key to avoid surprises!
Next: 2026-00909 — Allocation of Assets in Single-Employer Plans; Interest Assumptions for Valuing Benefits
Starting January 31, 2026, new rules change how single-employer pension plans calculate the value of benefits when plans end. These updated interest assumptions affect plan sponsors and the Pension Benefit Guaranty Corporation, helping make sure money values match real market prices. If you’re involved with these plans, expect more accurate numbers for payouts and possible impacts on withdrawal costs.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in